Five of these OTC were derived from BC patients bearing invasive ductal carcinoma (IDC), which is positive for estrogen receptor (ER+) and progesterone receptor (PR+) but negative for human epidermal growth factor receptor 2 (HER2-). Here, PGR is linked to invasive ductal breast carcinoma.